


## Supplementary Appendix:


### LFS TP1 MRD – older adults



Number at risk

|             |    |    |    |    |   |   |
|-------------|----|----|----|----|---|---|
| tp1_mrd=neg | 15 | 12 | 11 | 10 | 7 | 6 |
| tp1_mrd=pos | 13 | 9  | 4  | 3  | 3 | 1 |


### OS TP1 MRD – older adults



Number at risk

|             |    |    |    |    |   |   |
|-------------|----|----|----|----|---|---|
| tp1_mrd=neg | 15 | 14 | 13 | 10 | 7 | 7 |
| tp1_mrd=pos | 13 | 9  | 5  | 5  | 4 | 1 |


### TP1 MRD AYA – LFS



Number at risk

|              |    |    |    |    |    |    |
|--------------|----|----|----|----|----|----|
| tp1_mrd=Low  | 26 | 25 | 19 | 18 | 15 | 11 |
| tp1_mrd=High | 34 | 30 | 26 | 23 | 17 | 13 |


### TP1 MRD AYA - OS



Number at risk

|              |    |    |    |    |    |    |
|--------------|----|----|----|----|----|----|
| tp1_mrd=Low  | 26 | 25 | 23 | 21 | 18 | 13 |
| tp1_mrd=High | 34 | 32 | 27 | 24 | 20 | 13 |


### TP2 MRD AYA – LFS censored for CR1 SCT



Number at risk


|             |    |    |    |    |    |    |
|-------------|----|----|----|----|----|----|
| tp2_mrd=Neg | 41 | 35 | 26 | 24 | 16 | 10 |
| tp2_mrd=Pos | 26 | 7  | 5  | 5  | 3  | 2  |

### TP2 MRD AYA – OS censored for CR1 SCT




Number at risk

|             |    |    |    |    |    |    |
|-------------|----|----|----|----|----|----|
| tp2_mrd=Neg | 41 | 35 | 31 | 28 | 23 | 12 |
| tp2_mrd=Pos | 26 | 7  | 6  | 6  | 5  | 3  |

**TP2 MRD AYA – LFS censored for CR1 SCT**

Number at risk

tp2\_mrd=Neg 41 35 26 24 16 10  
 tp2\_mrd=Pos 14 2 2 2 1 0  
 tp2\_mrd=PBQR 12 5 3 3 2 2

**TP2 MRD AYA – OS censored for CR1 SCT**

Number at risk

tp2\_mrd=Neg 41 35 31 28 23 12  
 tp2\_mrd=Pos 14 2 2 2 2 1  
 tp2\_mrd=PBQR 12 5 4 4 3 2

**Figure 1:** LFS and OS in older adults by TP1 MRD negative vs positive; in AYA by TP1 MRD<sup>lo</sup> vs MRD<sup>hi</sup>; in AYA by TP2 MRD censored for CR1 SCT, with and without PBQR outcomes noted separately.

**Table 1: ALL treatment protocols used within real-world newly diagnosed cohort**

| PAEDIATRIC-INSPIRED PROTOCOLS |    | ADULT PROTOCOLS               |    |
|-------------------------------|----|-------------------------------|----|
|                               | n  |                               | n  |
| FRALLE93, FRALLE2000          | 15 | HyperCVAD                     | 27 |
| BFM95, BFM2000                | 35 | CALGB 8811/9111               | 5  |
| ALL06                         | 6  | GMALL 2002                    | 2  |
| ANZCHOG STUDY 8, STUDY 9      | 15 | EWALL-PH-01 without dasatinib | 1  |
| GMALL 05/93                   | 1  | LALA94                        | 3  |
| COG - AALL0434                | 1  |                               |    |